Clinical Trial Update: Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases [Phase 3]

View source ↗

Summary

Phase 3 trial of Alpharadin (radium-223 dichloride) in men with castration-resistant prostate cancer and bone metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Alpharadin (Radium-223 chloride)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED